Danaher returns a key business to growth, and we're raising our stock rating back to buy
Danaher's stock drop presents a buying opportunity. We're also increasing our price target.
In this photo illustration, a Danaher Corporation logo seen displayed on a tablet.
Igor Golovnov | SOPA Images | Lightrocket | Getty Images
Danaher shares declined Tuesday despite the life sciences company returning its key bioprocessing business to growth in the third quarter.